Cite
Moxifloxacin Pharmacokinetics, Cardiac Safety, and Dosing for the Treatment of Rifampicin-Resistant Tuberculosis in Children
MLA
Anneke C. Hesseling, et al. “Moxifloxacin Pharmacokinetics, Cardiac Safety, and Dosing for the Treatment of Rifampicin-Resistant Tuberculosis in Children.” Clinical Infectious Diseases, vol. 74, July 2021, pp. 1372–81. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....86403823ca107e0946d6865f749711d2&authtype=sso&custid=ns315887.
APA
Anneke C. Hesseling, Barend Fourie, Jana Winckler, H. Simon Schaaf, Anthony J Garcia-Prats, James C. Nielsen, Belén P. Solans, Stephanie Thee, Lubbe Wiesner, Louvina E van der Laan, Radojka M. Savic, Heather R. Draper, & Kendra K. Radtke. (2021). Moxifloxacin Pharmacokinetics, Cardiac Safety, and Dosing for the Treatment of Rifampicin-Resistant Tuberculosis in Children. Clinical Infectious Diseases, 74, 1372–1381.
Chicago
Anneke C. Hesseling, Barend Fourie, Jana Winckler, H. Simon Schaaf, Anthony J Garcia-Prats, James C. Nielsen, Belén P. Solans, et al. 2021. “Moxifloxacin Pharmacokinetics, Cardiac Safety, and Dosing for the Treatment of Rifampicin-Resistant Tuberculosis in Children.” Clinical Infectious Diseases 74 (July): 1372–81. http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....86403823ca107e0946d6865f749711d2&authtype=sso&custid=ns315887.